Prognostic Models to Predict Survival in Non-Small Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

PURPOSE: Determine prognostic factors and build a model to predict one-year overall survival (1Y-OS) and six-month progression free survival (6M-PFS) in advanced non-small cell lung cancer (NSCLC) patients treated with first-line paclitaxel and carboplatin (PC) with or without bevacizumab. MATERIALS...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Hoang, Tien, Dahlberg, Suzanne E., Sandler, Alan B., Brahmer, Julie R., Schiller, Joan H., Johnson, David H.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3433686/
https://ncbi.nlm.nih.gov/pubmed/22843087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e318260e106
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky